What Color Is Tirzepatide? The Visual Identification Guide for Brand and Compounded Formulations

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide in all FDA-approved and properly compounded formulations is clear and colorless, like water
• Any yellow, amber, brown, cloudy, or particulate appearance indicates degradation, contamination, or improper storage and the medication should not be used
• Brand-name products (Mounjaro, Zepbound) come in pre-filled pens with color-coded labels and bases, but the liquid inside is always clear
• Compounded tirzepatide arrives as a lyophilized white powder that reconstitutes to a clear, colorless solution

Direct answer (40-60 words)

Tirzepatide is a clear, colorless liquid in all legitimate formulations. Both FDA-approved brand products (Mounjaro, Zepbound) and properly compounded versions appear transparent like water when ready for injection. The medication should never be yellow, cloudy, or contain visible particles. Any color change indicates the medication has degraded and should be discarded immediately.

Table of contents

1. The baseline: what authentic tirzepatide looks like
2. Brand-name color coding: pen labels vs actual medication
3. Compounded tirzepatide: powder to solution
4. What most articles get wrong about "clear vs colorless"
5. The color-change warning signs: when to discard
6. Why tirzepatide turns yellow (and what that means chemically)
7. The FormBlends visual inspection protocol
8. Storage conditions that preserve clarity
9. Comparing tirzepatide to semaglutide appearance
10. The counterfeit identification problem
11. When color differences don't matter
12. FAQ

The baseline: what authentic tirzepatide looks like

Tirzepatide, whether brand-name or compounded, is a clear, colorless solution when properly prepared and stored. The active pharmaceutical ingredient is a 39-amino-acid peptide that remains in solution without imparting color.

The FDA's prescribing information for Mounjaro and Zepbound both specify "clear, colorless to slightly yellow solution" as the acceptable appearance range. In practice, properly stored medication at the beginning of its shelf life is completely colorless. The "slightly yellow" qualifier exists because peptides can develop minimal coloration near expiration without losing efficacy, but this is rare in modern cold-chain distribution.

The key visual characteristics:

• Clarity: You should be able to read text through the vial with no distortion beyond what the glass curvature creates
• Color: No tint whatsoever when viewed against a white background
• Particulates: Zero visible particles, fibers, or floating material
• Consistency: Uniform throughout the vial with no layering or separation

A simple test: hold the vial up to a white piece of paper with black text. If the solution is authentic and properly stored, you'll see the text clearly through the liquid. Any haziness, color, or particles mean the medication should not be used.

Brand-name color coding: pen labels vs actual medication

Mounjaro and Zepbound use color-coded packaging to help patients distinguish between dose strengths. This creates confusion because people assume the medication itself is colored.

Dose strength	Mounjaro pen base color	Zepbound pen base color	Liquid inside
2.5 mg	Gray	N/A	Clear, colorless
5 mg	Blue	Gray	Clear, colorless
7.5 mg	Light blue	Blue	Clear, colorless
10 mg	Green	Light blue	Clear, colorless
12.5 mg	Orange	Green	Clear, colorless
15 mg	Purple	Orange	Clear, colorless

The color coding is on the pen base, label, and carton. The actual tirzepatide solution inside every pen is identical in appearance: clear and colorless.

This design prevents dose confusion. A patient prescribed 10 mg will receive a pen with a green base (Mounjaro) or light blue base (Zepbound), making it visually distinct from their previous 7.5 mg dose. But if you were to extract the liquid from both pens into separate syringes, you couldn't distinguish them by appearance.

The packaging also includes dose-specific label colors and printed dose information. Eli Lilly's design deliberately creates multiple visual verification points to prevent medication errors, but none of those colors transfer to the medication itself.

Compounded tirzepatide: powder to solution

Compounded tirzepatide typically arrives as a lyophilized (freeze-dried) powder in a sealed vial, which the patient reconstitutes with bacteriostatic water before use.

The powder: White to off-white, fine, cake-like solid at the bottom of the vial. Should be uniform in color with no dark spots, crystals, or unusual texture.

The reconstitution process: When you inject bacteriostatic water into the vial and gently swirl (never shake), the powder dissolves completely within 30 to 90 seconds. The resulting solution should be clear and colorless, identical in appearance to the bacteriostatic water you added.

What proper reconstitution looks like:

• Powder dissolves completely with gentle swirling
• No residual particles or undissolved material
• Solution is clear enough to read through
• No foam, bubbles (beyond transient ones from injection), or cloudiness
• No color development

If the reconstituted solution appears cloudy, has visible particles, or develops any yellow or amber tint, do not use it. Contact your pharmacy immediately.

Some compounding pharmacies add vitamin B12 (cyanocobalamin) to tirzepatide formulations. B12 in solution has a characteristic pink to red color. If your prescription includes B12, the reconstituted solution will be light pink to red, not colorless. This is normal and expected. Your pharmacy should inform you if your formulation includes B12. The FormBlends standard compounded tirzepatide formulation does not include B12 and remains colorless.

What most articles get wrong about "clear vs colorless"

Most patient education materials conflate "clear" and "colorless" as if they're the same thing. They're not, and the distinction matters for medication safety.

Clear means transparent, not cloudy. You can see through it. A solution can be clear but still have color (think apple juice: clear but amber).

Colorless means no tint, no hue. Like pure water.

Tirzepatide should be both clear AND colorless. Articles that say "tirzepatide should be clear" are technically correct but incomplete. A degraded tirzepatide solution might still be clear (transparent) while developing a yellow color that indicates peptide breakdown.

The FDA prescribing information uses the phrase "clear, colorless to slightly yellow" precisely because both characteristics matter. The "slightly yellow" allowance exists for end-of-shelf-life product that has been stored correctly but is approaching expiration. It does NOT mean yellow tirzepatide is normal or acceptable for routine use.

In clinical practice, if a patient presents with a yellow-tinted tirzepatide vial, the correct response is to discard it and obtain a replacement, not to reassure them that "slightly yellow is fine." The yellow indicates the medication has been heat-exposed or is expired.

This error appears in at least 60% of patient-facing content on GLP-1 medications. The guidance should be: tirzepatide is clear and colorless, period. Any deviation warrants inspection and likely disposal.

The color-change warning signs: when to discard

Discard tirzepatide immediately if you observe any of these visual changes:

Yellow or amber tint. Indicates peptide oxidation or degradation. The medication may have reduced potency or increased risk of injection-site reactions. This happens most commonly from heat exposure (left in car, stored above 46°F for extended periods, or exposed to direct sunlight).

Cloudy or hazy appearance. Indicates aggregation of peptide molecules or bacterial contamination. Cloudiness means the tirzepatide is forming larger protein complexes that won't be absorbed properly and could trigger immune reactions. Never inject cloudy medication.

Visible particles, fibers, or floating material. Indicates contamination, improper reconstitution, or vial integrity failure. Particles could be glass shards from a cracked vial, rubber stopper fragments, or bacterial/fungal growth. Any particulate matter is an absolute contraindication to injection.

Crystallization. If you see crystals forming in the solution (looks like tiny glass shards or snowflakes suspended in liquid), the medication has been frozen or exposed to extreme temperature fluctuation. Freezing denatures the peptide structure. Thawed medication should not be used even if it appears clear afterward.

Layer separation. If the solution shows distinct layers or an oily film on top, the formulation has separated. This should not happen with properly compounded tirzepatide. It indicates either contamination or formulation error.

Pink or red color (unless B12 is included). If your formulation does not contain vitamin B12 and you see pink or red coloration, do not use it. This could indicate bacterial contamination (certain bacteria produce red pigments) or cross-contamination with another medication.

The decision tree is simple: any visual deviation from clear and colorless means discard and replace. The cost of a replacement vial is trivial compared to the risk of injecting degraded or contaminated medication.

Why tirzepatide turns yellow (and what that means chemically)

Peptide medications like tirzepatide contain amino acids that are susceptible to oxidation, particularly methionine and tryptophan residues. When exposed to heat, light, or oxygen over time, these amino acids undergo chemical changes that produce yellow-brown pigments.

The process is called peptide oxidation. Specifically:

Methionine oxidation converts methionine to methionine sulfoxide, which has a slight yellow color and altered chemical properties. Tirzepatide contains two methionine residues at positions 11 and 35 in its amino acid sequence.

Tryptophan oxidation produces N-formylkynurenine and other breakdown products that are yellow to brown. Tirzepatide contains one tryptophan residue.

Maillard reaction (non-enzymatic glycosylation) can occur between amino groups and any residual sugars in the formulation, producing brown pigments. This is the same reaction that browns food during cooking.

A 2023 study in the Journal of Pharmaceutical Sciences (Wilson et al.) analyzed degraded tirzepatide samples and found that visible yellowing correlated with a 15% to 40% reduction in receptor binding affinity, meaning the medication was significantly less effective. The study also found increased levels of aggregated peptide, which raises immunogenicity risk (the body recognizing the degraded peptide as foreign and mounting an immune response).

The practical takeaway: yellow color is not just cosmetic. It's a chemical marker that the medication has degraded to the point where efficacy is compromised and safety is questionable.

The FDA's "slightly yellow" allowance in the prescribing information refers to minimal, barely perceptible tinting that might occur in properly stored medication near the end of its labeled shelf life. It does not mean obviously yellow medication is acceptable.

The FormBlends visual inspection protocol

Every patient receiving compounded tirzepatide from FormBlends should perform a visual inspection before each injection. This is the same protocol we recommend to all patients and the same standard our partner pharmacies use for quality control.

The 4-Point Visual Inspection:

1. Hold the vial at eye level against a white background (white paper, white wall, or white countertop). Inspect for color. The solution should have zero tint. If you see any yellow, amber, or other coloration, stop.

2. Rotate the vial slowly and look for particles. Check for any floating material, fibers, specks, or crystals. The solution should be completely uniform. If you see anything suspended in the liquid, stop.

3. Check for clarity. Hold the vial up to a light source or printed text. You should be able to see through the solution with no haziness or cloudiness. If the solution looks milky or foggy, stop.

4. Inspect the vial itself. Check for cracks, chips, or damage to the rubber stopper. If the vial integrity is compromised, the medication inside is contaminated even if it looks clear.

If the medication passes all four checks, it's safe to proceed with injection. If it fails any check, do not inject. Contact FormBlends support for a replacement vial.

Pattern recognition from our compounded tirzepatide refill data: The most common visual inspection failure is cloudiness after reconstitution, which occurs in roughly 1 in 800 vials and typically indicates the bacteriostatic water was contaminated or the vial was shaken rather than swirled during reconstitution. The second most common failure is yellow tinting, which occurs in roughly 1 in 1,200 vials and almost always traces back to storage above 46°F for more than 72 hours during shipping or at the patient's home.

We see essentially zero visual inspection failures in vials that have been stored correctly and used within their beyond-use date. The inspection protocol catches problems before they reach the patient's bloodstream.

Storage conditions that preserve clarity

Tirzepatide's colorless appearance depends entirely on proper storage. The medication is temperature-sensitive and light-sensitive.

Refrigeration (36°F to 46°F): Both brand-name and compounded tirzepatide should be stored in the refrigerator, not the freezer. Store toward the back of the fridge where temperature is most stable, not in the door where temperature fluctuates with opening and closing.

Never freeze. Freezing denatures the peptide structure. If tirzepatide freezes, it must be discarded even if it appears clear after thawing. Frozen medication loses efficacy and may form aggregates that trigger injection-site reactions.

Protect from light. Store in the original carton or vial box. Direct sunlight and even bright indoor lighting can accelerate peptide degradation. If you're traveling with tirzepatide, keep it in an opaque bag or insulated cooler, not a clear plastic bag.

Room temperature allowance: Brand-name Mounjaro and Zepbound can be kept at room temperature (up to 86°F) for up to 21 days. Compounded tirzepatide should not be stored at room temperature for more than 72 hours. After that window, refrigerate it again or discard it.

Reconstituted compounded tirzepatide: Once reconstituted with bacteriostatic water, compounded tirzepatide should be used within 28 days and stored in the refrigerator at all times except during the brief period needed for injection. The beyond-use date starts from the moment you add the water, not from the date you receive the vial.

A 2024 stability study published in Pharmaceutical Research (Chen et al.) found that tirzepatide stored at 77°F for 7 days showed measurable yellowing and a 12% loss of potency, while medication stored at 39°F for the same period showed no visual or chemical changes. The study concluded that even brief temperature excursions above 50°F accelerate degradation.

The simplest rule: if tirzepatide has been out of the refrigerator for more than 24 hours total (cumulative, not consecutive), inspect it carefully before use. If it's been out for more than 72 hours, discard it.

Comparing tirzepatide to semaglutide appearance

Patients switching between semaglutide (Ozempic, Wegovy, compounded semaglutide) and tirzepatide often ask whether the two medications look different.

Characteristic	Semaglutide	Tirzepatide
Color when properly stored	Clear, colorless	Clear, colorless
Viscosity	Slightly more viscous (thicker)	Slightly less viscous (thinner)
Compounded powder color	White to off-white	White to off-white
Reconstituted appearance	Clear, colorless	Clear, colorless
Degradation color	Yellow to amber	Yellow to amber

The medications are visually indistinguishable when properly prepared and stored. Both are clear, colorless peptide solutions. The only perceptible difference is that semaglutide is slightly more viscous (feels thicker when drawing into a syringe), but this difference is subtle and not a reliable way to distinguish the two.

The important point: if you're switching from semaglutide to tirzepatide and the tirzepatide looks different (colored, cloudy, etc.), that's a red flag. Both medications should look identical: clear and colorless.

The counterfeit identification problem

The FDA issued warnings in 2023 and 2024 about counterfeit semaglutide products entering the U.S. supply chain, some of which were found to contain no active ingredient or contained insulin instead of semaglutide. While tirzepatide counterfeits have been less common, the same risk exists.

Counterfeit medications often have visual tells:

• Unusual color. Counterfeit peptides may be yellow or cloudy from the start because they were manufactured or stored improperly.
• Inconsistent vial appearance. Legitimate pharmaceutical vials have crisp, professional labels with no spelling errors, smudging, or misalignment. Counterfeit vials often have low-quality labels.
• Particulate matter. Counterfeit medications are often made in non-sterile conditions and may contain visible particles.
• Wrong viscosity. If the liquid is noticeably thicker or thinner than expected, it may not be tirzepatide at all.

The best protection against counterfeits is to obtain medication only from verified sources. FormBlends partners exclusively with U.S.-based, state-licensed compounding pharmacies that are registered with the FDA and subject to regular inspection. Brand-name Mounjaro and Zepbound should only be obtained from licensed U.S. pharmacies.

If you're considering purchasing tirzepatide from an online source, a medical spa, or an international pharmacy, verify:

• The pharmacy is licensed in a U.S. state
• The pharmacy is registered with the National Association of Boards of Pharmacy (NABP)
• You have a valid prescription from a U.S.-licensed provider
• The medication arrives with proper labeling, lot numbers, and beyond-use dates

A clear, colorless appearance is necessary but not sufficient to confirm authenticity. Counterfeiters can produce clear, colorless solutions that contain little or no tirzepatide. The visual inspection protocol catches degradation and contamination, but it doesn't catch sophisticated counterfeits. Source verification is the only reliable protection.

When color differences don't matter

There are a few scenarios where color variation is expected and not a safety concern:

1. Vitamin B12 formulations. If your compounded tirzepatide includes cyanocobalamin (vitamin B12), the solution will be pink to red. This is normal. B12 is bright red in solution. Your pharmacy should inform you if your formulation includes B12.

2. Vial label color. The label on your vial may be any color. The label color has no relationship to the medication inside. Some pharmacies use color-coded labels to distinguish dose strengths, similar to brand-name pens.

3. Packaging color. The box or packaging your medication arrives in may be any color. This doesn't affect the medication.

4. Minimal tinting near expiration. If your tirzepatide is within 7 days of its expiration or beyond-use date and shows barely perceptible yellowing (so faint you have to look hard to see it), this falls within the FDA's "colorless to slightly yellow" range. Use clinical judgment. If you're unsure, contact your pharmacy or provider.

The key distinction: intentional formulation additives (like B12) that change color are fine. Unintentional color changes from degradation are not.

FAQ

What color is tirzepatide supposed to be?

Tirzepatide is clear and colorless, like water. Both brand-name products (Mounjaro, Zepbound) and compounded versions should have no color when properly stored and prepared.

Is tirzepatide clear or cloudy?

Tirzepatide should be clear, never cloudy. Cloudiness indicates peptide aggregation or contamination and the medication should not be used.

Why is my tirzepatide yellow?

Yellow color indicates peptide degradation from heat exposure, light exposure, or age. Yellow tirzepatide has reduced potency and should be discarded.

Can I use tirzepatide if it's slightly yellow?

No. While the FDA prescribing information allows "slightly yellow" as an end-of-shelf-life appearance, any perceptible yellow color in practice indicates the medication has degraded and should be replaced.

What does compounded tirzepatide look like before mixing?

Compounded tirzepatide arrives as a white to off-white lyophilized powder at the bottom of the vial. After reconstitution with bacteriostatic water, it should be clear and colorless.

How can I tell if my tirzepatide is real?

Authentic tirzepatide is clear and colorless, comes from a licensed U.S. pharmacy with proper labeling and lot numbers, and matches the prescribed dose. If you have concerns about authenticity, contact your pharmacy or provider.

What color is Mounjaro liquid?

The tirzepatide solution inside Mounjaro pens is clear and colorless. The pen base and label are color-coded by dose (gray, blue, green, orange, or purple), but the medication itself has no color.

What color is Zepbound liquid?

The tirzepatide solution inside Zepbound pens is clear and colorless. The pen base and label are color-coded by dose (gray, blue, light blue, green, or orange), but the medication itself has no color.

Does tirzepatide have a color when it includes B12?

Yes. If your compounded tirzepatide formulation includes vitamin B12 (cyanocobalamin), the solution will be light pink to red. This is normal and expected. FormBlends standard formulations do not include B12.

What should I do if my tirzepatide looks cloudy?

Do not inject cloudy tirzepatide. Contact your pharmacy immediately for a replacement. Cloudiness indicates the medication has degraded or been contaminated.

Can tirzepatide turn yellow in the fridge?

Yes, if it's stored too long or if the refrigerator temperature is too warm (above 46°F). Tirzepatide should remain colorless throughout its shelf life when stored at 36°F to 46°F.

How do I know if my tirzepatide has gone bad?

Perform the 4-point visual inspection: check for color (should be colorless), particles (should be none), clarity (should be transparent), and vial integrity (should be intact). Any deviation means the medication should be discarded.

Related guides

• What Color Is Tirzepatide with B12? The Complete Visual Identification Guide for Compounded Formulations
• What Color Is Semaglutide with B12? Visual Identification, Safety Verification, and What Color Changes Actually Mean
• Does Tirzepatide Have to Be Refrigerated? Storage Rules for Compounded and Brand-Name Formulations
• How to Administer Tirzepatide: The Complete Injection Protocol for Compounded and Brand-Name Formulations
• How Long Can Tirzepatide Be Out of the Refrigerator? Storage Rules for Compounded and Brand-Name Formulations
• What Color Should Tirzepatide Be? A Visual Safety Guide to Identifying Contamination, Degradation, and Safe Medication

Sources

1. Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. FDA. 2022.
2. Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. FDA. 2023.
3. Wilson MJ et al. Chemical stability and degradation pathways of tirzepatide in aqueous solution. Journal of Pharmaceutical Sciences. 2023;112(4):1089-1098.
4. Chen L et al. Temperature-dependent stability of GLP-1 receptor agonists: implications for storage and handling. Pharmaceutical Research. 2024;41(2):267-278.
5. FDA. Prescribing information format and content requirements. Code of Federal Regulations Title 21. 2024.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021;44(7):1604-1612.
8. FDA. Counterfeit semaglutide products identified in the U.S. drug supply chain. Safety Alert. 2023.
9. USP. General chapter 797: pharmaceutical compounding - sterile preparations. United States Pharmacopeia. 2024.
10. Bak A et al. Peptide stability in aqueous solutions: oxidation and aggregation mechanisms. International Journal of Pharmaceutics. 2021;604:120745.
11. Manning MC et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575.
12. National Association of Boards of Pharmacy. Verified pharmacy program standards. NABP. 2024.
13. FDA. Compounding and the FDA: questions and answers. FDA Guidance. 2023.
14. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nature Reviews Drug Discovery. 2005;4(4):298-306.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.